III Memorial “Alicia Pueyo” Workshop
Research on DIPG
Barcelona, February 26th 2015

Venue:
ABBA GARDEN HOTEL   C/Santa Rosa, 33   08950 Esplugues de Llobregat
(Just beside Hospital Sant Joan de Déu)

Final Agenda

Session 1: The clinical challenges of current DIPG management.
8:30 AM to 9:30 AM

1. KATHERINE E.WARREN. Pediatric Oncology Branch, NCI. National Institute of Health. Bethesda, USA
   How poised is DIPG for envisioning cure? (20’)

2. MAURA MASSIMINO. Istituto Nazionale dei Tumori
   Current clinical management of DIPG: Nimotuzumab plus Vinorelbine, radiation and beyond. (15’)

3. BEATE TIMMERMANN. Westdeutsches Protonentherapiezentrum Essen
   Radiotherapy strategies for the management of DIPG patients. (15’)

Session 2: First biopsy and genomics
9:30 AM to 11:45 PM

4. MARK KIERAN. Dana-Farber Cancer Institute and Children’s Hospital Boston. USA
   Genomic advances in the understanding of DIPG and its translational opportunities. The USA perspective. (30’)

5. JACQUES GRILL. Institut de cancérologie Gustave Roussy.
   Genomic advances in the understanding of DIPG and its translational opportunities. The European perspective. (30’)

Short Abstract Presentation 1 (Oral selection)

Break 1: 10:45 to 11:00 AM Coffee Break

Sponsored by:
Session 3: Clinical trials. How to measure progress.
11:00 to 13:30 PM

6. DANNIS VAN VUURDEN. VU University Medical Center Amsterdam.
Survival prediction model for DIPG. International consensus?. (30’)

7. SANNA-MARIA KIVIVUORI. Helsinki University Central Hospital
Current clinical management of DIPG: anti angiogenic strategies (30’)

8. STEVE LOWIS. University Hospital of Bristol
Development of an implantable catheter system for repeated cycles of CED in pediatric DIPG (30’)

9. MARK M. SOUWEDAIN. Weill Medical College of Cornell University
CED strategies for DIPG control. How close?. (30’)

Short Abstract Presentation 2 (Oral selection)

Break 2 13:30 to 14:30 PM  Lunch

Session 4: Let's start the future.
14:30 to 16:30 PM

10. CHRIS JONES. The Institute of Cancer Research, Sutton.
Genomic advances in the understanding of DIPG and its translational opportunities: ACVR1 and beyond. (30’)

11. RINTARO HASHIZUME. Feinberg School of Medicine. Northwestern U. Chicago
Epigenetic approaches to target DIPG (30’)

12. OREN BECHER. Duke Cancer Center
Genetically engineered mouse modeling of DIPG. Translational opportunities. (30’)

13. ANGEL M. CARCABOSO. Developmental tumor Laboratory. HSJD
HSJD Xenograft animal model for DIPG. (20’)

Short Abstract Presentation 3 (Oral selection)

Break 3: 16:30 to 16:45 PM  Coffee

Sponsored by:
Session 5: Immunotherapy approaches: hurdles and achievements.
16:45 to 18:00 PM

14. IAN POLLACK. Children’s Hospital of Pittsburgh
Immunotherapy approaches for children with DIPG: present and future developments. (30’)

15. STEFAAN VAN GOOL. University Hospital Leuven
Oncolytic virotherapy and cellular immunotherapy against DIPG. Translational opportunities. (30’)

16. ANDRES MORALES. Pediatric Neuro-Oncology. HSJD Barcelona.
HSJD Dendritic cell vaccine protocol. (15’)

Short Abstract Presentation 4(Oral selection)

Closing session: The families support and impulse.
18:15 to 18:30 PM

GLORIA GARCIA (Alicia’s mother).